Topical corticosteroids for hives and itch (urticaria): Systematic review and Bayesian meta-analysis of randomized trials

• Published in: Annals of allergy, asthma, & immunology Vol. 133; no. 4; pp. 437 - 444.e18
• Main Authors: Chu, Alexandro W.L., Rayner, Daniel G., Chu, Xiajing, Chen, Lina, Dong, Audrey Y.H., Waserman, Susan, Baker, Diane R., Sheikh, Javed, Moellman, Joseph, Lang, David M., Ben-Shoshan, Moshe, Mathur, Sameer K., Beck, Lisa A., Khan, David A., Oliver, Eric T., Asiniwasis, Rachel N., Chan, Jeffrey, Cole, Emily F., Trayes, Kathryn P., Frazier, Winfred T., Runyon, Lauren, Wheeler, Kathryn E., Eftekhari, Sanaz, Gardner, Donna D., Winders, Tonya, Bernstein, Jonathan A., Saini, Sarbjit S., Chu, Derek K.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2024
• Subjects: Administration, Topical; Adrenal Cortex Hormones - administration & dosage; Adrenal Cortex Hormones - therapeutic use; Adult; Bayes Theorem; Humans; Pruritus - drug therapy; Randomized Controlled Trials as Topic; Urticaria - drug therapy
• ISSN: 1081-1206; 1534-4436; 1534-4436
• DOI: 10.1016/j.anai.2024.06.003

Topical corticosteroids are widely used as a treatment for itch and wheals (urticaria), but their benefits and harms are unclear.
To systematically synthesize the benefits and harms of topical corticosteroids for the treatment of urticaria.
We searched MEDLINE, EMBASE, and CENTRAL from database inception to March 23, 2024, for randomized trials comparing topical corticosteroids with placebo for patients with urticaria (either chronic spontaneous or inducible urticaria or acute urticaria elicited from skin/intradermal allergy testing). Paired reviewers independently screened records, extracted data, and assessed risk of bias. Random-effects meta-analyses addressed urticaria severity, itch severity (numeric rating scale; range 0-10; higher is worse), and adverse events. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach informed certainty of evidence ratings. PROSPERO registration: CRD42023455182.
A total of 19 randomized controlled trials enrolled 379 participants with a median of mean age of 30.1 (range 21.1-44.0) years. Compared with placebo, topical corticosteroids may reduce wheal size (ratio of means 0.47, 95% CI 0.38-0.59; low certainty) and itch severity (mean difference −1.30, 95% CI −5.07 to 2.46; very low certainty). Topical corticosteroids result in little to no difference in overall adverse events (94 fewer patients per 1000, 95% credible intervals 172 fewer to 12 more; high certainty).
Compared with placebo, topical corticosteroids may result in a reduction of wheal size and little to no difference in overall adverse events. Topical corticosteroids may reduce itch severity, but the evidence is very uncertain. Future large, randomized trials addressing the use of topical corticosteroids would further support optimal urticaria management.